UNSPSC 85743014: Supplement cul-de-sac with nonautologous tissue substitute, open approach

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement cul-de-sac with nonautologous tissue substitute, open approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0UUF0KZ

UNSPSC 85743014 Supplement cul-de-sac with nonautologous tissue substitute, open approach is a Commodity code that shows no recent state and local procurement activity aligned with its nominal medical-procedure scope. The six recent opportunities tagged under this code—independent medical evaluation services for pension boards, surgical benefit carve-out programs for municipal employees, occupational medical surveillance for ferries operations, emergency and specialty medical services for youth in custody, pharmacy benefit management, and temporary health professional staffing—represent administrative healthcare procurement (benefits administration, staffing coordination, and occupational health programs) rather than clinical surgical procedures or tissue-substitute supply. None of these solicitations involve the supply of nonautologous tissue substitutes or surgical supplementation work that the code nominally describes.

The mismatch between the code's clinical procedure name and the actual work being solicited suggests either systematic misclassification in the state and local procurement system or that this particular Commodity code does not reflect current public-sector buying patterns. Geographic activity appears dispersed across Arizona (City of Phoenix), California (City of Long Beach, County of Santa Clara), Washington (WSDOT), Florida (Collier County), and Texas (Harris County), but without opportunities that substantively match the code's stated purpose, geographic concentration or issuing-body patterns are not actionable for business development. Firms pursuing clinical medical-product or tissue-substitute supply contracts should verify code assignment in specific RFPs rather than rely on this code as a reliable categorization vehicle.